文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-PSMA放射性配体治疗实践模式的差异与共识:95家诊疗一体化中心的国际调查

Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers.
PubMed 文献 · J Nucl Med · 2024-03-01

该国际调查通过62项问卷评估了95家诊疗一体化中心在177Lu-PSMA治疗中的操作差异与相似性,问卷于2022年6月发出,211家受邀中心中95家(45%)完成。结果显示各中心在患者选择、给药活度和疗效评估策略上存在机构间差异,作者认为在患者和诊疗中心数量预期增加的背景下,方案标准化或协调及专门培训是可取的。

要点

  • 95家中心完成问卷,多数位于欧洲(51%),其次为美洲(22%)和亚洲(22%)。
  • PSMA PET治疗资格最常用68Ga-PSMA-11判定(77%),资格标准以主观定性评估最多(33%)。
  • 每周期平均标准注射活度为7.3 GBq(范围5.5-11.1 GBq),65%中心采用标准化疗效评估标准。

核心结论

  • 该国际调查显示各机构在177Lu-PSMA放射性核素治疗的多个方面存在差异,包括患者选择、给药活度和疗效评估策略。
  • 作者认为,在患者数量和诊疗一体化中心数量预期增加的背景下,方案标准化或协调及专门培训是可取的。

研究设计与样本

  • 本研究为国际问卷调查,问卷含62个条目,由5名医师组成的核心团队设计并经国际专家外部评审。
  • 2022年6月发出参与邀请邮件,去除重复后每家中心仅保留一份有效回复;211家受邀中心中95家(45%)完成问卷。
  • 调查内容涵盖中心信息、患者选择、放射性药物、治疗前后临床评估、实验室值、治疗终止、治疗后影像及一般信息。

主要发现

  • 参与中心多数位于欧洲(51%),其次为美洲(22%)和亚洲(22%)。
  • 研究前12个月内,95家参与中心共5,906例患者接受177Lu-PSMA治疗,其中欧洲2,840/5,906例(48%)、亚洲1,313/5,906例(22%)、大洋洲1,225/5,906例(21%)。
  • PSMA PET治疗资格最常用68Ga-PSMA-11判定(77%);在84家按临床标准诊疗、同情用药或本地研究方案开展的中心中,额外治疗前影像包括18F-FDG PET/CT 41家(49%)、CT 27家(32%)、肾显像25家(30%)、骨显像13家(15%)。
  • 在42家参与企业申办试验的中心中,额外治疗前影像包括18F-FDG PET/CT 11家(26%)、CT 25家(60%)、肾显像9家(21%)、骨显像28家(67%)。
  • PSMA PET资格标准包括主观定性评估PSMA阳性(33%中心)、VISION标准(23%)和TheraP标准(13%);每周期平均标准注射活度为7.3 GBq(范围5.5-11.1 GBq)。

关键数值与推荐

  • PSMA PET治疗资格判定最常用68Ga-PSMA-11(77%中心)。
  • PSMA PET资格标准:主观定性评估PSMA阳性33%中心、VISION标准23%中心、TheraP标准13%中心。
  • 每周期平均标准注射活度为7.3 GBq(范围5.5-11.1 GBq)。
  • 65%中心采用标准化疗效评估标准,PSMA PET进展标准应用最多(37%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy effectively treats metastatic castration-resistant prostate cancer. Patients requiring treatment, and consequently the number of theranostic centers, are expected to increase significantly after Food and Drug Administration and European Medicines Agency approval. This requires standardization or harmonization among theranostic centers. The aim of this study was to assess operational differences and similarities among 177Lu-PSMA treatment centers. Methods: A questionnaire comprising 62 items, designed by a core team of 5 physicians and externally reviewed by international experts, was developed. Study participants were asked to provide answers about their center, patient selection, radiopharmaceuticals, clinical assessment before and after 177Lu-PSMA treatments, laboratory values, treatment discontinuation, posttreatment imaging, and general information. An invitation e-mail to participate in the study was sent in June 2022. Duplicates were removed to allow for only one valid response per center. Results: Ninety-five of 211 (45%) contacted centers completed the questionnaire. Most participating centers were in Europe (51%), followed by America (22%) and Asia (22%). During the 12 mo before this study, a total of 5,906 patients received 177Lu-PSMA therapy at the 95 participating centers. Most of these patients were treated in Europe (2,840/5,906; 48%), followed by Asia (1,313/5,906; 22%) and Oceania (1,225/5,906; 21%). PSMA PET eligibility for 177Lu-PSMA was determined most frequently using 68Ga-PSMA-11 (77%). Additional pretherapy imaging included 18F-FDG PET/CT, CT, renal scintigraphy, and bone scintigraphy at 41 (49%), 27 (32%), 25 (30%), and 13 (15%), respectively, of the 84 centers for clinical standard of care, compassionate care, or local research protocols and 11 (26%), 25 (60%), 9 (21%), and 28 (67%), respectively, of the 42 centers for industry-sponsored trials. PSMA PET eligibility criteria included subjective qualitative assessment of PSMA positivity at 33% of centers, VISION criteria at 23%, and TheraP criteria at 13%. The mean standard injected activity per cycle was 7.3 GBq (range, 5.5-11.1 GBq). Sixty-two (65%) centers applied standardized response assessment criteria, and PSMA PET Progression Criteria were the most applied (37%). Conclusion: Results from this international survey revealed interinstitutional differences in several aspects of 177Lu-PSMA radionuclide therapy, including patient selection, administered activity, and the response assessment strategy. Standardization or harmonization of protocols and dedicated training are desirable in anticipation of increasing numbers of patients and theranostic centers.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Farolfi A, Armstrong WR, Djaileb L, et al. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J Nucl Med. 2024. PMID: 38238041. doi:10.2967/jnumed.123.266391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。